admin_moehs2

admin_moehs2

Moehs Group at the Pharmaceutical Manufacturing Catskills Training 2024

On 15th of November, Moehs Group team had the pleasure of collaborating in the Pharmaceutical Manufacturing Catskills 2024 training, organized at INS La Romànica, in Barberà del Vallès. A day full of learning for all participants, who worked on the manufacture of an ibuprofen suspension for children, demonstrating the talent and dedication of future professionals […]

Moehs Group at the Pharmaceutical Manufacturing Catskills Training 2024 Read More »

Moehs Group and EUROAPI sign an exclusive agreement for the production of Metamizole in Europe.

Moehs Group, a leading international group in the production of active pharmaceutical ingredients, has signed an exclusive agreement with EUROAPI to take over the production of Metamizole, the active ingredient of Nolotil, at its facilities in Spain. This exclusive agreement between Moehs Group and EUROAPI aims to complete the evaluation of the technical transfer of

Moehs Group and EUROAPI sign an exclusive agreement for the production of Metamizole in Europe. Read More »

2 GRANTS FROM CENTRO PARA EL DESARROLLO TECNOLÓGICO Y LA INNOVACIÓN

The Administration Board of the Centro para el Desarrollo Tecnológico y la Innovación, E.P.E (CDTI), has approved 2 important grants for Moehs Group: ABROCITINIB: development of a new chemical synthesis method of a janus kinase inhibitor active ingredient for the treatment of atopic dermatitis. VERICIGUAT: the objective is to develop a new method of chemical

2 GRANTS FROM CENTRO PARA EL DESARROLLO TECNOLÓGICO Y LA INNOVACIÓN Read More »

Proyectoo S3 Industria

PARTICIPATION IN S3 INDUSTRY PROJECT

Moehs Group participates in the S3 Indústria project together with teachers from the Chemistry department of the Institutes Federica Montseny (Burjassot, Valencia) and Dr. Peset Aleixandre (Paterna, Valencia). With this project, thanks to the #ConvocatoriaDualiza of CaixaBank, it aims to generate new learning situations on the subject of air pollution. The first day of the

PARTICIPATION IN S3 INDUSTRY PROJECT Read More »

PROJECT NITROSO-SITAGLIPTIN IMPURITY

We are proud to announce that the Moehs Research and Development project regarding nitroso-Sitagliptin impurity has been published by the scientific Journal of Separation Science Plus. This a very important step if we take into consideration that this impurity is classified as a potentially genotoxic impurity. The pharma industry is still facing the nitrosamines nightmare.

PROJECT NITROSO-SITAGLIPTIN IMPURITY Read More »